May 20th 2024
Jose Lutzky, MD, discussed the promise of tumor infiltrating lymphocyte therapy for difficult-to-treat advanced melanoma.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
CAR T-Cell Therapy Poised to Become Routine Care in CLL
August 13th 2019The initial pilot study of CTL019 in heavily pretreated CD19-positive hematologic malignancies demonstrated the feasibility of CAR T-cell therapy in patients with CLL. A presentation at the 2019 American Society of Gene & Cell Therapy Annual Meeting reported 2 cases of chemotherapy-resistant CLL, with ongoing follow- up at 8 years showing persistence of CAR-engineered T cells and sustained remission, as determined by flow cytometry and deep sequencing of immunoglobulin H rearrangements.
Read More
Four-Year Follow-Up Data Confirm Durable Responses With CAR T-Cell Therapy in B-Cell Lymphomas
August 7th 2019In an interview with <em>Targeted Oncology</em>, Chong, a fellow at the University of Pennsylvania, discussed the 4-year follow-up data for CAR T cells in patients with DLBCL and FL. She also addressed the challenges that need to be overcome in order to give more patients access to this type of therapy.
Read More
Phase III Trial Investigating Adjuvant Cemiplimab in High-Risk CSCC
August 6th 2019A phase III clinical trial has begun to investigate the use of cemiplimab as an adjuvant treatment after surgery and radiation therapy in patients with high-risk cutaneous squamous cell carcinoma.<br />
Read More
MRD Reported Undetectable After Liso-cel CAR T-cell Therapy in CLL
August 2nd 2019In the phase I/II TRANSCEND CLL 004 study, chimeric antigen receptor T-cell therapy lisocabtagene maraleucel led to undetectable minimal residual disease in patients with relapsed/refractory chronic lymphocytic leukemia.
Read More
Bempegaldesleukin Plus Nivolumab Granted Breakthrough Designation in Melanoma by the FDA
August 1st 2019The combination of bempegaldesleukin and nivolumab was granted a breakthrough therapy designation by the FDA for the treatment of patients with previously untreated unresectable or metastatic melanoma.
Read More
Assessing the Role CAR T-cell Therapy Plays in Mantle Cell Lymphoma Treatment in ZUMA-2 Trial
July 31st 2019Kieron Dunleavy, MD, discussed current approaches to treating patients with MCL, highlighting peer discussions on the subject and information about the ZUMA-2 trial, in an interview with <em>Targeted Oncology</em>.
Read More
Survival Benefit With Nivolumab Still Seen at 5 Years in Melanoma, RCC, and NSCLC
July 31st 2019Nivolumab demonstrated long-term survival benefit in heavily pretreated patients with advanced melanoma, renal cell carcinoma, and non–small cell lung cancer, according to an analysis of 5-year results from the CA209-003 trial. The analysis also identified favorable and adverse factors associated with survival that could inform future use of nivolumab.
Read More
Analysis Demonstrates Correlation Between Presence of ctDNA and Survival in Melanoma
July 26th 2019David Polsky, MD, PhD, discusses the findings from a liquid biopsy analysis of the COMBI-d trial, which is a phase III trial investigating the combination of dabrafenib and trametinib or dabrafenib alone in patients with BRAF V600E/K–mutant melanoma. Investigators found an association between the presence of baseline circulating tumor DNA (ctDNA) and a poor prognosis with the treatment of BRAF inhibitors.
Watch
International Consortium Defines Guidelines for Conducting Neoadjuvant Trials in Melanoma
July 26th 2019In an interview with Targeted Oncology, Rodabe N. Amaria, MD, discussed the guidelines and recommendations outlined by the INMC. She also highlighted the importance of genomic testing in the neoadjuvant setting of melanoma.
Read More
Pavlik Reviews Immunotherapy for Cutaneous Carcinomas in Case Studies
July 24th 2019Anna C. Pavlick, DO, MS, MBA, spoke with a group of physicians about the systemic therapy options, including immunotherapeutics, for treating patients with cutaneous carcinomas in a recent <em>Targeted Oncology </em>live case-based peer perspectives discussion. Pavlick explained treatment options based on 2 case scenarios of patients with cutaneous malignancies.
Read More
Biomarker Analysis Confirms Clinical Validity of ctDNA Monitoring in Advanced Melanoma
July 22nd 2019In an interview with <em>Targeted Oncology</em>, David Polsky, MD, PhD, discussed the findings from this analysis in patients with <em>BRAF</em>-mutant, unresectable, metastatic melanoma. He highlighted the next steps necessary for validating these findings and potentially using ctDNA to help inform treatment decisions for patients with metastatic melanoma.
Read More
Pembrolizumab for cSCC Testing Against Placebo In KEYNOTE-630 Trial
July 10th 2019In an interview with <em>Targeted Oncology</em>, Shlomo Koyfman, MD, the director of head and neck and skin cancer radiation at Cleveland Clinic, provides details about the current treatments for cSCC and how the new KEYNOTE-630 trial could improve practice for oncologists who treat cSCC.
Read More
Intralesional Oncolytic Viruses Harness in situ Immunization for Cutaneous Melanoma
July 8th 2019The ability to activate pattern recognition receptors, carry other genetic “cargo” to modify immunity, and induce lymphocyte infiltration into cancer is an appealing strategy accomplished by intralesional oncolytic viruses. Thus, the concept of combining these novel therapeutics in the preoperative setting to enhance in situ immunization and antitumor activity systemically, as well as to increase R0 complete resection, may be a useful approach to lead to cure, according to Robert L. Ferris, MD, PhD.
Read More